Ezastatin

Indication :

INDICATIONS AND USAGE

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

1.1 Primary Hyperlipidemia

EZASTATIN is indicated for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.

1.2 Homozygous Familial Hypercholesterolemia (HoFH)

Ezastatin is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.

Composition :

Ingredients:

Atorvastatin (As Calcium Trihydrate)

Ezetimibe

Inactive Ingredients:

Microcrystalline Cellulose(Avicel PH 102), Lactose monohydrate 200 mesh, Povidone K30, Sodium lauryl Sulfate, Croscarmellose Sodium, Butylated Hydroxyanisole, Magnesium Stearate, Hypromellose 2910 E5, Polyethylene Glycol 6000, Titanium Dioxide (C.I : 77891), Talc.